Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:47:07 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:INAB - IN8BIO INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
INAB - Q0.20.95·1.060.11.05+0.055.0129.11252260.99  1.05  0.993.9499  0.65Apr 18Apr 1615 min RT 2¢

Recent Trades - Last 10 of 226
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-16 16:05U:INABNews ReleaseIN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
2024-04-09 16:30U:INABNews ReleaseIN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
2024-03-14 16:00U:INABNews ReleaseIN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
2024-03-05 16:30U:INABNews ReleaseIN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
2024-02-26 08:00U:INABNews ReleaseIN8bio to Present at Upcoming Investor Conferences
2024-02-14 08:00U:INABNews ReleaseIN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
2024-01-04 08:00U:INABNews ReleaseIN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
2023-12-11 16:05U:INABNews ReleaseIN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
2023-12-11 09:01U:INABNews ReleaseIN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
2023-12-07 08:00U:INABNews ReleaseIN8bio Appoints Dr. Corinne Epperly to Board of Directors
2023-12-05 08:00U:INABNews ReleaseIN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia
2023-11-20 07:00U:INABNews ReleaseIN8bio ¢ € ™s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
2023-11-10 07:00U:INABNews ReleaseIN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting
2023-11-09 16:00U:INABNews ReleaseIN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-06 08:00U:INABNews ReleaseIN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
2023-11-03 12:00U:INABNews ReleaseIN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
2023-11-02 09:17U:INABNews ReleaseIN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
2023-11-01 08:00U:INABNews ReleaseIN8bio to Participate at the 2023 Truist Securities BioPharma Symposium
2023-10-12 08:00U:INABNews ReleaseIN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
2023-09-29 08:00U:INABNews ReleaseIN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting